Ono Pharmaceutical (OTCMKTS:OPHLF) Sets New 1-Year Low – Should You Sell?

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $9.22 and last traded at $9.22, with a volume of 20200 shares changing hands. The stock had previously closed at $10.51.

Ono Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 3.22 and a quick ratio of 2.80. The stock has a 50-day moving average price of $10.38 and a two-hundred day moving average price of $12.51. The stock has a market cap of $4.33 billion, a PE ratio of 6.88 and a beta of 0.59.

Ono Pharmaceutical (OTCMKTS:OPHLF) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.24 earnings per share for the quarter. Ono Pharmaceutical had a net margin of 19.64% and a return on equity of 11.85%. The company had revenue of $824.42 million for the quarter.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.